



## Sneha Ramakrishna

Instructor, Pediatrics - Hematology & Oncology

### CLINICAL OFFICES

- **Pediatric Hematology and Oncology**

725 Welch Rd

MC 5913

Palo Alto, CA 94304

**Tel** (650) 497-8953

**Fax** (650) 497-8959

### Bio

---

#### BIO

Sneha Ramakrishna, M.D., is an Instructor of Pediatrics in the Division of Hematology and Oncology. Dr. Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. She completed her residency training in Pediatrics at the Children's Hospital of Philadelphia and her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program. Her research focuses on identifying mechanisms of relapse in patients following chimeric antigen receptor (CAR) T cell therapies and optimizing both CAR design and tumor sensitivity to improve long-term success of CAR T cell therapies. Clinically, Dr. Ramakrishna sees patients with pediatric solid tumors and treats children with CAR T cell therapies in the Cancer Cellular Therapies program.

#### CLINICAL FOCUS

- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Instructor, Pediatrics - Hematology & Oncology

#### HONORS AND AWARDS

- Clinical Scientist Research Career Development Award (K08), National Cancer Institute (2022-2027)
- Young Investigator Award, Hyundai Hope on Wheels (2020-2022)
- ASH Abstract Achievement Award, American Society of Hematology (2017)
- Research Scholar, Howard Hughes Medical Institute (2010)

#### PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2019)
- Board Certification, American Board of Pediatrics , Hematology/Oncology (2019)
- Board Certification: Pediatrics, American Board of Pediatrics (2015)
- Fellowship: Johns Hopkins and National Cancer Institute Ped Hematology and Oncology Training (2018) MD

- Residency: Children's Hospital of Philadelphia Pediatric Residency (2015) PA
- Medical Education: Case Western Reserve School of Medicine (2012) OH

## Research & Scholarship

---

### CLINICAL TRIALS

- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG), Recruiting
- Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies, Recruiting
- CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies, Not Recruiting

## Publications

---

### PUBLICATIONS

- **MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS**  
Monje, M., Majzner, R., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Barsan, V., Richards, R., Campen, C., Reschke, A., Toland, et al  
OXFORD UNIV PRESS INC.2022: 20-21
- **GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.** *Nature*  
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, et al  
2022
- **CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy**  
Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., Chinnasamy, H., Younes, S. F., Oak, J. S., Natkunam, Y., Reynolds, W. D., Iglesias, M., Crawford, et al  
AMER SOC HEMATOLOGY.2021
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*  
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al  
2021
- **Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia.** *Pediatric blood & cancer*  
Marquez, C. P., Montiel-Esparza, R., Hui, C., Schultz, L. M., Davis, K. L., Hoppe, R. T., Donaldson, S. S., Ramakrishna, S., Hiniker, S. M.  
2020: e28870
- **Using single-cell analysis to predict CAR T cell outcomes.** *Nature medicine*  
Ramakrishna, S., Shah, N. N.  
2020
- **Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement** *JACC: CARDIOONCOLOGY*  
Han, B., Montiel-Esparza, R., Chubb, H., Kache, S., Schultz, L. M., Davis, K. L., Ramakrishna, S., Su, L.  
2020; 2 (4): 666–70
- **Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.** *Journal for immunotherapy of cancer*  
Schultz, L., Patel, S., Davis, K. L., Ramakrishna, S., Sahaf, B., Bhatia, N., Baggott, C., Erickson, C., Majzner, R. G., Oak, J., Bertaina, A., Mackall, C., Feldman, et al  
2020; 8 (2)
- **Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic.** *Pediatric blood & cancer*  
Ding, Y., Ramakrishna, S., Long, A. H., Phillips, C. A., Montiel-Esparza, R., Diorio, C. J., Bailey, L. C., Maude, S. L., Aplenc, R., Batra, V., Reilly, A. F., Rheingold, S. R., Lacayo, et al  
2020: e28427

- **Prospects and Challenges for Use of CAR T Cell Therapies in Solid Tumors.** *Expert opinion on biological therapy*  
Ramakrishna, S., Barsan, V., Mackall, C.  
2020
- **Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.** *Current oncology reports*  
Barsan, V., Ramakrishna, S., Davis, K. L.  
2020; 22 (2): 11
- **Supercharging your CAR.** *Blood*  
Ramakrishna, S. n., Davis, K. L.  
2020; 135 (9): 593–94
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*  
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al  
2020
- **Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Ramakrishna, S. n., Highfill, S. L., Walsh, Z. n., Nguyen, S. M., Lei, H. n., Shern, J. F., Qin, H. n., Kraft, I. L., Stetler-Stevenson, M. n., Yuan, C. M., Hwang, J. D., Feng, Y. n., Zhu, et al  
2019
- **Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22** *MOLECULAR THERAPY-ONCOLYTICS*  
Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., Yuan, C. M., Haso, W., Shern, J. F., Shah, N. N., Fry, T. J.  
2018; 11: 127–37
- **CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.** *Nature medicine*  
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M. n., Yuan, C. M., Ramakrishna, S. n., Wolters, P. n., Martin, S. n., Delbrook, C. n., Yates, B. n., Shalabi, H. n., Fountaine, T. J., Shern, et al  
2017
- **Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas** *CANCER IMMUNOLOGY RESEARCH*  
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., Mackall, C. L.  
2016; 4 (10): 869-880